Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Head of Troubled CDC Anthrax Lab Resigns

July 23, 2014 2:09 pm | News | Comments

The head of the government lab which potentially exposed workers to live anthrax has resigned, an agency spokesman said Wednesday. Michael Farrell was head of the Centers for Disease Control and Prevention lab since 2009. He submitted his resignation Tuesday, the spokesman said. Read more...

TOPICS:

Survey Finds Sharp Increase in Teen HGH Use

July 23, 2014 1:31 pm | by David Crary, AP National Writer | News | Comments

Experimentation with human growth hormones by America's teens more than doubled in the past year, as more young people looked to drugs to boost their athletic performance and improve their looks, according to a new survey. Read more...     

TOPICS:

FDA Approves Gilead's Zydelig for Three Cancers

July 23, 2014 1:13 pm | News | Comments

The Food and Drug Administration on Wednesday approved a new cancer drug from Gilead Sciences Inc. to treat chronic lymphocytic leukemia, follicular lymphoma and small lymphocytic lymphoma. Read more...            

TOPICS:
Advertisement

Neurotrophic Keratitis Drug Gets Orphan Drug Designation

July 23, 2014 11:26 am | News | Comments

Dompe, a leader in R&D for new therapeutic solutions for the treatment of rare diseases, announced that rhNGF (Recombinant Human Nerve Growth Factor) has been designated as an orphan drug by the American Food and Drug Administration. Read more...

TOPICS:

Shire to Spend About $225M on Drug Collaboration

July 23, 2014 11:20 am | News | Comments

The drugmaker Shire plans to spend about $225 million in a joint effort with a privately held, U.S. firm to develop a potential treatment for the rare and life-threatening genetic disorder Hunter syndrom, said the British company Wednesday. Read more...

TOPICS:

Genes Play a Role in Radiation Survival

July 23, 2014 11:16 am | News | Comments

A team of researchers from the University of Wisconsin have identified 46 genes in Escherichia coli that are necessary for its survival at exceptionally high levels of radiation. The paper appears ahead of print in the Journal of Bacteriology. Read more...

TOPICS:

Biosceptre Posts Positive Results for Basal Cell Carcinoma Drug

July 23, 2014 11:07 am | News | Comments

Biosceptre, the oncology company developing antibody products that target the nf-P2X7 receptor, announced positive results from its Phase 1 trial to assess the safety and tolerability of BIL-010t, a topically administered, highly purified sheep antibody therapy, to treat Basal Cell Carcinoma. Read more...

TOPICS:

Merck Strengthens Commitment to Chinese Market

July 23, 2014 11:01 am | News | Comments

Merck, a leading company for high-tech products in the pharmaceutical and chemical sectors, reiterated its commitment to investments in the Chinese market, strengthening a major pillar of its emerging markets growth strategy. Read more...   

TOPICS:
Advertisement

Autoimmune Disorders, Cancer Share Apoptosis Inhibitors

July 23, 2014 10:53 am | News | Comments

Autoimmune disorders may share certain pathogenic mechanisms with cancer, according to a new report by George Washington University researcher Linda Kusner, Ph.D., published in PLOS ONE, showing that the very same inhibitors of apoptosis, or cell destruction, in tumors are also expressed in cells that produce autoimmune diseases. Read more...

TOPICS:

Galmed Gets IND Clearance for Fatty Liver Treatment

July 22, 2014 2:47 pm | News | Comments

Galmed Pharmaceuticals Ltd. announced that FDA cleared Galmed's Investigational New Drug application, permitting the company to conduct clinical trials of aramchol in the United States for the treatment of fatty liver disorders. Read more...   

TOPICS:

Halozyme Resumes Pancreatic Cancer Trial

July 22, 2014 2:37 pm | News | Comments

Halozyme Therapeutics Inc. announced that it has resumed enrollment and dosing of patients in its ongoing Phase 2 trial (Study 202) evaluating PEGPH20 in patients with pancreatic cancer. Read more...               

TOPICS:

FDA Fast Tracks New Epilepticus Drug

July 22, 2014 2:26 pm | News | Comments

SAGE Therapeutics announced that the FDA has granted fast track designation to the SAGE-547 development program, which will facilitate the development and expedite the review of the drug candidate. Read more...          

TOPICS:

Potential Flu Drugs Target Immune Response, Not Virus

July 22, 2014 2:07 pm | News | Comments

The seriousness of disease often results from the strength of immune response, rather than with the virus, itself. Turning down that response, rather than attacking the virus, might be a better way to reduce that severity. Read more...         

TOPICS:

HIV Pills Show More Promise to Prevent Infection

July 22, 2014 1:47 pm | News | Comments

There is more good news about HIV treatment pills used to prevent infection in people at high risk of getting the AIDS virus: Follow-up from a landmark study that proved the drug works now shows that it does not encourage risky sex and is effective even if people skip some doses. Read more...

TOPICS:

Easing Drug-Induced Fatty Liver Disease in HIV Patients

July 22, 2014 1:40 pm | News | Comments

The only drug to receive FDA approval for reduction of the abdominal fat deposits that develop in some patients receiving antiviral therapy for HIV infection may also reduce the incidence of fatty liver disease. Read more...        

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading